Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature

Abstract

BackgroundGastric cancer (GC) still represents the third leading cause of cancer-related death worldwide. Peritoneal relapse (PR) is the most frequent metastasis occurring among patients with advanced gastric cancer. Increasingly more evidence have clarified the tumor immune microenvironment (TIME) may predict survival and have clinical significance in GC. However, tumor-transcriptomics based immune signatures derived from immune profiling have not been established for predicting the peritoneal recurrence of the advanced GC.MethodsIn this study, we depict the immune landscape of GC by using transcriptome profiling and clinical characteristics retrieved from GSE62254 of Gene Expression Omnibus (GEO). Immune cell infiltration score was evaluated via single-sample gene set enrichment (ssGSEA) analysis algorithm. The least absolute shrinkage and selection operator (LASSO) Cox regression algorithm was used to select the valuable immune cells and construct the final model for the prediction of PR. The receiver operating characteristic (ROC) curve and the Kaplan-Meier curve were used to check the accuracy of PRIs. Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed to explore the molecular pathways associated with PRIs.ResultsA peritoneal recurrence related immune score (PRIs) with 10 immune cells was constructed. Compared to the low-PRIs group, the high-PRIs group had a greater risk. The upregulation of the focal adhesion signaling was observed in the high-PRIs subtype by GSEA and KEGG. Multivariate analysis found that both in the internal training cohort and the internal validation cohort, PRIs was a stable and independent predictor for PR. A nomogram that integrated clinicopathological features and PRIs to predict peritoneal relapse was constructed. Subgroup analysis indicated that the PRIs could obviously distinguish peritoneal recurrence in different molecular subtypes, pathological stages and Lauren subtypes, in which PRIs of Epithelial-Mesenchymal Transitions (EMT) subtype, III-IV stage and diffuse subtype are higher respectively.ConclusionOverall, we performed a comprehensive evaluation of the immune landscape of GC and constructed a predictive PR model based on the immune cell infiltration. The PRIs represents novel promising feature of predicting peritoneal recurrence of GC and sheds light on the improvement of the personalized management of GC patients after surgery.

A Novel DNA Repair Gene Signature for Immune Checkpoint Inhibitor-Based Therapy in Gastric Cancer

“…In the emerging immunotherapy strategies such as the ICB therapy in various types of cancer, the interaction of tumor DNA damage and repair landscape with patient immune system and related therapy has recently been revealed as a complex biological process ( Fridman et al, 2012 ; Gentles et al, 2015 ; Mouw et al, 2017 ; Bever and Le, 2018 ; Joshi and Badgwell, 2021 ; Zhang et al, 2021 ). Nevertheless, many prognostic and predictive biomarkers are being evaluated clinically to identify criteria for establishing customized therapeutic approaches.…”

Extracellular Matrix-Associated Pathways Promote the Progression of Gastric Cancer by Impacting the Dendritic Cell Axis

“…Chen et al 27 reported a ten-immune-related gene signature with a 1-year AUC of 0.681 and even failed to reach 0.57 in the GSE15459 cohort and 0.559 in the GSE84437 cohort; these results are not acceptable. Zhang et al 28 reported an immune signature in the GSE62254 cohort, with an AUC value of only 0.793 in the entire cohort. Izumi et al 29 constructed a gene expression-based 15-gene signature to distinguish lymph node status and obtained an AUC value of only 0.829 in the GSE62254 cohort.…”

Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis

“…Other groups have studied specific patterns of the TME to develop metabolic, 79 immune, 80 and collagen 81 signatures predictive of GCPM. In a more comprehensive, transcriptomewide analysis, a six-gene panel predictive of both synchronous and metachronous GCPM has been identified.…”